Principal Financial Group Inc. raised its holdings in shares of Sangamo Therapeutics by 6.8% during the second quarter. Piper Jaffray Cos. cut shares of Sangamo BioSciences from an “overweight” rating to a “neutral” rating and lowered their price target for the company from $9.00 to $5.00 in a report on Wednesday, October 19th. Total debt to equity ratio of Aveo Pharmaceuticals (NASDAQ:AVEO) for most recent quarter is 0 whereas long term debt to equity ratio for most recent quarter is 0.
Several other institutional investors have also modified their holdings of the stock. The portion of a company’s profit allocated to each outstanding share of common stock was $6.29 a share in the trailing twelve months. Following the completion of the transaction, the director now owns 31,800 shares in the company, valued at $456,966. Geode Capital Management LLC increased its position in Sangamo Therapeutics by 3.1% during the first quarter. Dimensional Fund Advisors LP now owns 128,764 shares of the biopharmaceutical company’s stock worth $670,000 after purchasing an additional 513 shares during the last quarter. Sangamo Therapeutics, Inc. (SGMO) has shown a downward trend during time of recent session. The company’s stock had a trading volume of 1,462,156 shares, compared to its average volume of 1,278,731. However, -23.84% over the last one month, 20.00% for the last quarter and year to date performance stands at 303.28%. The shares were sold at an average price of $15.25, for a total transaction of $228,750.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Convergys Corporation (CVG) analysts on average have given a price target of $14.6 on CVG stock. The disclosure for this sale can be found here. In the final minutes of trading on Thursday, shares hit $12.30, more than tripling in the last 12 months. Baldwin Brothers Inc Ma owns 1,500 shares. (SGMO) has 83.61M billion shares outstanding. If you happen to be reading this article on another website, it was stolen and illegally republished in violation of USA and worldwide copyright law. The legal version of this report can be accessed at https://weekherald.com/2017/11/10/northern-trust-corp-acquires-44656-shares-of-sangamo-therapeutics-inc-sgmo.html.
The stock of Sangamo Therapeutics Incorporated (NASDAQ:SGMO) registered a decrease of 5.1% in short interest. (SGMO) opened at $12.30 on Friday. The company’s net profit margin has achieved the current level of 0 percent and possesses 0 percent gross margin.
Sangamo BioSciences (NASDAQ:SGMO) last released its quarterly earnings results on Wednesday, October 26th. The business had revenue of $8.30 million during the quarter, compared to analyst estimates of $5.82 million. The company’s quarterly revenue was up 124.3% on a year-over-year basis. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by $0.02.
A number of key analysts, polled by FactSet, shared their views about the current stock momentum. ValuEngine raised shares of Sangamo Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, August 11th. Wells Fargo & Company reiterated an “outperform” rating and set a $30.00 price objective (up previously from $20.00) on shares of Sangamo Therapeutics in a research report on Tuesday, September 5th. 2 have given the stock a Hold rating, 0 as Underperform and 0 as Sell. Zacks Investment Research upgraded Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 target price for the company in a report on Friday, August 18th. One analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the company. At the moment, the average analyst price target is $14.60.
Sangamo Therapeutics, Inc., formerly Sangamo BioSciences, Inc., is a clinical-stage biotechnology company.